Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

940 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703).
Fukumoto SI, Oizumi S, Harada M, Sukoh N, Nakano K, Fuke S, Sakakibara-Konishi J, Takamura K, Ito K, Fujita Y, Nishigaki Y, Harada T, Akie K, Kinoshita I, Amano T, Isobe H, Dosaka-Akita H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Fukumoto SI, et al. Cancer Chemother Pharmacol. 2020 Jul;86(1):117-127. doi: 10.1007/s00280-020-04104-1. Epub 2020 Jun 20. Cancer Chemother Pharmacol. 2020. PMID: 32564128 Clinical Trial.
A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405.
Inoue A, Ishimoto O, Fukumoto S, Usui K, Suzuki T, Yokouchi H, Maemondo M, Kanbe M, Ogura S, Harada T, Oizumi S, Harada M, Sugawara S, Fukuhara T, Nukiwa T. Inoue A, et al. Among authors: fukumoto s. Ann Oncol. 2010 Apr;21(4):800-803. doi: 10.1093/annonc/mdp384. Epub 2009 Oct 13. Ann Oncol. 2010. PMID: 19825887 Free article. Clinical Trial.
Clinical characteristics of pleomorphic carcinoma of the lung.
Ito K, Oizumi S, Fukumoto S, Harada M, Ishida T, Fujita Y, Harada T, Kojima T, Yokouchi H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Ito K, et al. Among authors: fukumoto s. Lung Cancer. 2010 May;68(2):204-10. doi: 10.1016/j.lungcan.2009.06.002. Epub 2009 Jul 3. Lung Cancer. 2010. PMID: 19577320 Free article.
Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601.
Akie K, Oizumi S, Ogura S, Shinagawa N, Kikuchi E, Fukumoto S, Harada M, Kinoshita I, Kojima T, Harada T, Fujita Y, Ohsaki Y, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Akie K, et al. Among authors: fukumoto s. Oncology. 2011;81(2):84-90. doi: 10.1159/000331681. Epub 2011 Oct 3. Oncology. 2011. PMID: 21968255 Free article. Clinical Trial.
Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations.
Oizumi S, Sugawara S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Watanabe S, Ito K, Gemma A, Demura Y, Fukumoto S, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Aiba K, Nukiwa T. Oizumi S, et al. Among authors: fukumoto s. ESMO Open. 2018 Feb 23;3(2):e000313. doi: 10.1136/esmoopen-2017-000313. eCollection 2018. ESMO Open. 2018. PMID: 29531840 Free PMC article.
Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers.
Onimaru R, Shirato H, Shimizu S, Kitamura K, Xu B, Fukumoto S, Chang TC, Fujita K, Oita M, Miyasaka K, Nishimura M, Dosaka-Akita H. Onimaru R, et al. Among authors: fukumoto s. Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):126-35. doi: 10.1016/s0360-3016(03)00095-6. Int J Radiat Oncol Biol Phys. 2003. PMID: 12694831 Clinical Trial.
940 results